已收盤 11-20 16:00:00 美东时间
-1.500
-6.18%
Aprea Therapeutics announced updated results from its Phase 1 trial of APR-1051, a WEE1 inhibitor, showing clinical activity, safety, and pharmacokinetics supporting once-daily dosing. Among 56 patients, two confirmed partial responses were observed in uterine cancers, with durable stable disease in five others. Pharmacodynamic data demonstrated WEE1 target engagement across doses. Aprea plans to expand enrollment in uterine serous carcinoma and ...
11-20 14:00
Aprea Therapeutics reported Q3 2026 financial results with $37.8 million in cash and provided updates on its WEE1 inhibitor APR-1051, which is advancing in a Phase 1 clinical trial expanded to nine sites. The company plans to present interim Phase 1 data at the EORTC-NCI-AACR Symposium in November 2026 and expects to select the dose for Part 2 in early 2027. APR-1051 is being evaluated in biomarker-defined cancers, with a focus on endometrial can...
11-04 13:30
The Trump administration is pushing to re-evaluate a key permit for Ørsted's (DNNGY) Revolution Wind project that began operating this year off the Rhode Island coast, Bloomberg reported Tuesday. Acco...
10-14 08:15
The Trump administration is said to have appealed a federal court ruling that blocked the EPA from sending California’s landmark vehicle emissions rules to the Republican-controlled Congress for a fas...
09-16 13:24
The U.S. Environmental Protection Agency said Monday it will repeal some carbon dioxide emission rules for power plants, the latest step in the Trump administration's broader effort to curb the agency...
09-15 08:20
The Paris climate agreement goal of limiting the rise in global temperatures to 1.5 degrees Celsius is no longer feasible and likely will be exceeded within the next few years, according to a report r...
09-06 09:15